Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?

The success of immunotherapy that targets inhibitory T cell receptors for the treatment of multiple cancers has seen the anti-tumor immune response re-emerge as a promising biomarker of response to therapy. Longitudinal characterization of T cells in the tumor microenvironment (TME) helps us understand how to promote effective anti-tumor immunity. However, serial analyses at the tumor site are rarely feasible in clinical practice.

Citation:
Principe N, Kidman J, Lake RA, Lesterhuis WJ, Nowak AK, McDonnell AM, et al. Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity? Front Oncol. 2021;11.

Keywords:
T cells; checkpoint receptors; immune checkpoint therapy; malignant pleural effusions (MPE); memory T cells

Abstract:
The success of immunotherapy that targets inhibitory T cell receptors for the treatment of multiple cancers has seen the anti-tumor immune response re-emerge as a promising biomarker of response to therapy. Longitudinal characterization of T cells in the tumor microenvironment (TME) helps us understand how to promote effective anti-tumor immunity. However, serial analyses at the tumor site are rarely feasible in clinical practice.